Variant · Snv

KRAS Q61H

CI-VAR-00003565Explore in graph →NP_004976.2:p.Gln61HisNM_004985.4:c.183A>CClinVar 177881 CIViC 907 rs17851045

Curated evidence

Evidence by cancer (8 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–8 of 8 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma1
KRAS Q61H	Vemurafenib	Predictive	D	Supports Resistance	—	submitted	EID3865 In an in vitro study, the H460C cell line expressing a KRAS Q61H mutation was associated with resistance to vemurafenib treatment. Resistance was determined by assessing cell viability and phosphoryla… (full text at CIViC) PMID 25706985 · Joshi et al., 2015 · Open in CIViC	civic
Malignant Colorectal Neoplasm6
KRAS Q61H	Cetuximab	Predictive	B	Supports Resistance	3	submitted	EID2227 In irinotecan-resistant metastatic colorectal cancer patients who had been treated with cetuximab and irinotecan, KRAS mutations in codon 61 or 146 were associated with shorter progression-free surviv… (full text at CIViC) PMID ·

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
177881	Conflicting classifications of pathogenicity	criteria provided, conflicting classifications	1	Non-small cell lung carcinoma; Juvenile myelomonocytic leukemia; Cardiovascular phenotype; RASopathy; Neoplasm; Primary intracranial sarcoma, DICER1-mutant; Colorectal cancer; Pilocytic astrocytoma; Embryonal rhabdomyosarcoma; KRAS-related disorder	germline/somatic	10